Skip to main content
. 2016 Nov 21;52(4):520–533. doi: 10.1007/s00535-016-1285-y

Fig. 2.

Fig. 2

Rate of sustained virologic response at 12 weeks (SVR12) in patients receiving elbasvir (EBR; 50 mg) plus grazoprevir (GZR; 50 or 100 mg) in part 1 and in noncirrhotic and cirrhotic patients receiving EBR at a dose of 50 mg plus GZR at a dose of 100 mg (immediate-treatment group, ITG, only) in part 2 (full analysis set). SVR12 rates are not yet available for the deferred-treatment group. CI confidence interval